Skyhawk Therapeutics
PrivateLast Round
Series B
Sep 14, 2021
Total Funding Raised
$141M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Skyhawk Therapeutics is a biotechnology company that develops small molecule drugs aimed at correcting ribonucleic acid expression through proprietary technology that targets specific binding sites during the splicing process to address diseases caused by exon skipping.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Skyhawk Therapeutics Comparables
Compare Skyhawk Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Arrakis Therapeutics | 89% | |
| Expansion Therapeutics | 83% | |
| Remix Therapeutics | 81% | |
Skyhawk Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 14, 2021 | ||||
| VC Round | Jun 26, 2018 | ||||
| Seed | Jan 23, 2018 |
Skyhawk Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GreatPoint Ventures | Series B, VC Round |
| Agent Capital | VC Round |
| Good Growth Capital | Seed |
| Bramalea Partners | Series B |
| Acks | Seed |
| GreatPoint Ventures | VC Round |
| Fidelity Management & Research Company | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 10, 2026
Aaron Deves appointed to lead commercialization efforts for SKY-0515.
- Aug 18, 2025
Will develop RNA-targeting small molecules for neurological diseases.
Skyhawk Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Skyhawk Therapeutics's valuation, stock price, and market status.